Could common bladder medications change how men ejaculate? a study investigates

NCT ID NCT07736560

First seen Jul 30, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study looks at whether antimuscarinic drugs used for overactive bladder (OAB) affect how long ejaculation lasts and the time before a man can ejaculate again. Researchers will follow men aged 20 to 50 who are prescribed tolterodine or propiverine for OAB. Participants fill out questionnaires before treatment and again at one and two months. The goal is to see if these bladder medications have any unintended effects on sexual function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
antimuscarinic drugs (tolterodine or propiverine) used for overactive bladder
What this could lead to
If the study finds a link, it could help doctors choose OAB treatments that minimize sexual side effects in men.
What could go wrong
This is a small observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all men.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EJACULATION ABNORMAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Başakşehir Çam and Sakura City Hospital, Department of Urology

    Istanbul, Istanbul, 34200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.